Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

standing common and participating - diluted 1,635 1,635 (1) "As Reconciled" to exclude purchase accounting adjustments, special and acquisition-related items and other specified items. 

    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to Common Shareholders and Diluted Earnings per
    Common Share
    (Amounts in Millions)

    "As Reconciled" amounts related to Net income available to common
    shareholders and Diluted earnings per common share reflect the following
    adjustments:

                                            Second Quarter      Six Months
                                              (unaudited)      (unaudited)
                                              -----------      -----------
                                            2009       2008   2009     2008
                                            ----       ----   ----     ----
    Purchase accounting adjustments:
    --------------------------------
         Amortization of intangibles in
          connection with the acquisition
          of Organon BioSciences (a)        $122       $138   $241     $270
         Depreciation related to the fair
          value adjustment of fixed
          assets related to the
          acquisition of Organon
          BioSciences (b)                     13          8     23       16
         Charge related to the fair value
          adjustment to inventory related
          to the acquisition of Organon
          BioSciences (a)                      -        211      -      762
                                               -        ---      -      ---
    Total purchase accounting
     adjustments, pre-tax                    135        357    264
'/>"/>
SOURCE  Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)The Scientist, a leading scientific magazine covering the life sciences, ranked Photometrics’ Evolve “Intelligent” EMCCD camera fourth among the publication’s “Top 10 Inn
Breaking Biology Technology:Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
...I and Endovascular Forum Launch Interactive, Case-...ide Learning and Collaboration , , LAS VEGAS, May...e complication, another physician has likely seen ...iovascular Angiography and Interventions (SCAI) an...es Company, today unveiled a new educational Websi...
...TTLE, May 6 Dendreon Corporation (Nasdaq: DNDN ...ed March 31, 2009. Revenue for the first quarter ...arter ended March 31, 2008. , , Dendreon,s tota...rch 31, 2009 were $17.0 million compared to $19.2 ... for the quarter ended March 31, 2009 was $15.4 mi...
...MBRIDGE, Mass. May 5, 2009 Researchers at the Ha...SEAS), in collaboration with researchers from Worc...ed, for the first time, that the activation energy...ted by the surrounding dielectric and can be modif.... , The finding, published in the April 6 issue o...
Other Biology Technology:New Website Connects Physicians to Solve Challenging Cases and Share Experiences 2New Website Connects Physicians to Solve Challenging Cases and Share Experiences 3New Website Connects Physicians to Solve Challenging Cases and Share Experiences 4Dendreon Reports First Quarter 2009 Financial Results 2Dendreon Reports First Quarter 2009 Financial Results 3Dendreon Reports First Quarter 2009 Financial Results 4Dendreon Reports First Quarter 2009 Financial Results 5Scientists demonstrate effect of confining dielectrics on semiconductor nanowire conductivity 2
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smo
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Increased nicotine levels detected in those who light-up earlier 2Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences 5493 1Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences 5493 2Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences 5493 3New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law 59490 1New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law 59490 2New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law 59490 3American Academy of Physician Assistants Applauds Senate Finance Committee for Advancing Health Reform Legislation 59488 1American Academy of Physician Assistants Applauds Senate Finance Committee for Advancing Health Reform Legislation 59488 2
...dence suggesting an alternative form of natural vi...lood in humans at levels determined to protect aga...rs naturally in eight different forms. The primary...ol, or TCP. But another natural form of vitamin E ...eated Ohio State University Medical Center studies...
...g smoking can improve lung function test scores by... The findings appear in the second issue for July ...itical Care Medicine, published by the American Th...Departments of Respiratory Medicine and Immunology...s studied 11 asthmatics who continued to smoke and...
...hildren under age 6 in Massachusetts over 22 years...n--especially infants--are now more likely to be o...of Ambulatory Care and Prevention of Harvard Medic...ars in the July issue of Obesity. , "The obesity e... children," says Matthew Gillman, MD, senior autho...
Other Biology News:Natural vitamin E tocotrienol reaches blood at protective levels 2Natural vitamin E tocotrienol reaches blood at protective levels 3Quitting smoking improves lung function considerably 2Today's babies are fatter babies 2
Rabbit Anti-Human acetyl-Histone H3 (Lys 4) Antibody, Unconjugated from Upstate
Anti-gp64 Antibody, Unconjugated from Novagen
Mouse Anti-Mouse Ly 6C.2(Ly 28.2) Monoclonal Antibody, Unconjugated, Clone 5075-3.6 from CEDARLANE Laboratories Limited
Rabbit Anti-b-Catenin, phospho (Ser675) Antibody, Unconjugated from Spring Bioscience
Biology Products: